Jason M. Werner

Jason M. Werner brings 20+ years of multi-disciplinary experience within Life Sciences, Technology and Finance, prior to joining Kera Therapeutics Inc. as President and CEO. Mr. Werner most recently completed his tenure at Eyevance Pharmaceuticals as Co-Founder and Chief Operating Officer. He led the company through a successful strategic exit as Eyevance was acquired by Santen Pharmaceutical Co., Ltd. for $225mm in an all-cash transaction in September 2020. In addition to the sale of Eyevance, Mr. Werner led the spin out of Amber Ophthalmics from Eyevance in conjunction with the Santen transaction that enabled 2 programs to continue forward in clinical development, providing investors an additional liquidity opportunity. While at Eyevance, Mr. Werner was responsible for Corporate Strategy, Technical Operations, Product Development and Corporate Development & Licensing. In addition to the successful exit, Mr. Werner executed 7 transactions at Eyevance, resulting in 10 commercialized and development stage assets over a 26 month period. .

Prior to Eyevance Pharmaceuticals, Mr. Werner served as the Vice President of Strategy & Commercial Development for Sun Ophthalmics, a division within Sun Pharmaceutical Industries, Ltd. . He led the ophthalmic business on numerous strategic transactions, including the acquisition of Ocular Technologies Sarl, which brought OTX-101 (CEQUA®) to Sun, as well as the takeover of Insite Vision in 2015. In addition to Eyevance and Sun, Mr. Werner has additional, escalating experience in Ophthalmics; such as, Foresight Biotherapeutics, Nicox and Inspire Pharmaceuticals. He has executed over US$1.5bn in transactions at the various companies.

In concert to his industry achievements, Mr. Werner has spent time in global domain consulting within the Life Sciences focused on Commercial Solutions. Mr. Werner’s efforts were primarily focused on Collaboration and Patient Centric Solutions for Global Pharmaceutical clients.

His career started in Finance and Big Pharma and has worked for Pfizer and Fidelity Management and Research over the course of his career in various positions. He holds a Bachelor of Science in Business Administration from the University of New Hampshire.